Rachel Teitelbaum, PhD
Rachel Teitelbaum, PhD is the founder of Hervana Ltd. and acting chief executive officer of the company. Rachel earned her Ph.D. in microbiology and immunology at the Sue Golding Graduate Division of the Albert Einstein College of Medicine. Her academic research career spans more than 15 years and focused on research in infectious diseases, the development of animal models of infection and the development of vaccines for mucosal immunity. Rachel is also a registered patent agent in several jurisdictions and also serves as the Intellectual Property Advisor to Hervana.
David Fredricks, M.D.
Director of the Fredricks Laboratory in the Vaccine and Infectious Diseases Institute in the Fred Hutchinson Cancer Research Center at the University of Washington School of Medicine; which focuses on the human vaginal microbiome.
Jos Seegers, PhD.
Dr. Seegers is the CEO of Falco Biotherapeutics and former CEO of Lactrys Biopharmaceuticals BV., whose work focuses on plasmid replication and stability in Lactococcus lactis and the exploitation of a library of affinity proteins, expressed at the surface of lactobacilli .
Joyce Frey-Vasconcells, PhD
Dr. Frey-Vasconcells served more than 12 years at the FDA, most recently as Deputy Director, Office of Cellular, Tissue, and Gene Therapies (OCTGT) with the Center for Biologics Evaluation and Research (CBER).